Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina

• Status: Completed
• Trial end date: 2018-09-03
• Target enrollment: 0
• Participant gender: Male

Summary

Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Androgens; Hormones

Criteria

Inclusion Criteria:

• Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual clinical practice

• Written informed consent

Exclusion Criteria:

• Contraindications to Firmagon

• Patients already on Firmagon therapy